In the dynamic world of biotech, Summit Therapeutics has been a beacon of success, with its shares skyrocketing over 1,000% in the past three years. This extraordinary growth has been fueled by the development of their flagship oncology drug, ivonescimab. A product originally licensed from the Chinese firm, Akeso Biopharma, ivonescimab has proven its mettle […]
Category: Axsome Therapeutics
Unveiling Axsome Therapeutics: Analyst Insights
The biotech stage is bustling with activity and at the forefront, striding with confident strides, is the clinical-stage biopharmaceutical company, Axsome Therapeutics Inc. With a laser-sharp focus on creating innovative therapies for central nervous system (CNS) disorders that are currently met with limited treatment options, Axsome is carving a niche for itself in the biotech […]
